CXCL12 and neoplasm: To characterize the tumor/tumor microenvironment, CXCR4-CXCL12-CXCR7 were evaluated in the epithelial and stromal compartment of 308 advanced EOC patients enrolled in the MITO16A/MaNGO-OV2 trial [25,27].